SCHEMBL140203

SCHEMBL140203

COc1ccc(-c2cc(C(N)=O)c3[nH]c4cc(OCCN(C)C)ccc4c3n2)cc1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
JAK2 O60674 16/20 0.60
DYRK3 O43781 1/20 0.49
MAP4K4 O95819 1/20 0.49
PIM1 P11309 1/20 0.49
RPS6KB1 P23443 1/20 0.49
CSNK2A1 P68400 1/20 0.49
PKN2 Q16513 1/20 0.49
PIM3 Q86V86 1/20 0.49
BRSK1 Q8TDC3 1/20 0.49
AURKB Q96GD4 1/20 0.49
HIPK2 Q9H2X6 1/20 0.49
CLK4 Q9HAZ1 1/20 0.49
MKNK2 Q9HBH9 1/20 0.49
STK17A Q9UEE5 1/20 0.49
MAP4K5 Q9Y4K4 1/20 0.49
MAOA P21397 1/20 0.46
FLT3 P36888 1/20 0.45
PARP1 P09874 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL144158 0.92 DYRK3 (0.54) JAK2DYRK3MAP4K4PIM1RPS6KB1
SCHEMBL140179 0.90 JAK2 (0.66) JAK2MAOAPARP1
SCHEMBL142463 0.87 JAK2 (0.77) JAK2PARP1
SCHEMBL142210 0.84 JAK2 (0.63) JAK2MAOAFLT3PARP1
SCHEMBL141989 0.83 JAK2 (0.68) JAK2PARP1
SCHEMBL141226 0.82 JAK2 (0.56) JAK2MAOA
SCHEMBL140965 0.80 JAK2 (0.69) JAK2MAOA
SCHEMBL140316 0.79 JAK2 (0.54) JAK2
SCHEMBL142655 0.78 JAK2 (0.78) JAK2
SCHEMBL141522 0.77 JAK2 (0.80) JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 JAK2 1/4885DYRK3 326/4885MAP4K4 191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.